Vendor profile
Gilead Sciences Finland Oy
FI- Awards
- 12
- Total awarded value
- €247,334,000
- Countries
- countries.FI
- Latest award
- Jan 12, 2026
- Expiring within 12 months
- 1
Award history
| Date | Buyer | Title | Category | Value | Country | Expires | Source |
|---|---|---|---|---|---|---|---|
| 01/12/2026 | Pohjois-Pohjanmaan hyvinvointialue | Finland – Pharmaceutical products – Hepcludex (bulevirtidi) -lääkevalmisteen valinta ajalle 1.4.2025-31.12.2025 Pohjois-Pohjanmaan hyvinvointialueen lääkehankintarenkaalle. | — | €64.0K | FI | 12/31/2025 | View on TED ↗ |
| 11/18/2025 | HUS Group, the joint authority for Helsinki and Uusimaa | Finland – Pharmaceutical products – CAR-T-soluterapiavalmisteet hankintakaudelle 1.1.2026 – 31.12.2027 | — | €20.0M | FI | 12/31/2027 | View on TED ↗ |
| 02/10/2025 | HUS Group, the joint authority for Helsinki and Uusimaa | Finland – Antineoplastic and immunomodulating agents – CAR-T-soluterapiavalmisteet hankintakaudelle 1.1.2025 – 31.12.2025 | — | €33.0M | FI | 12/31/2025 | View on TED ↗ |
| 01/13/2025 | HUS Group, the joint authority for Helsinki and Uusimaa | Finland – Pharmaceutical products – Breksukabtageeni autoleuseeli -valmisteen (Tecartus® 0,4 – 2 × 108 solua infuusioneste, dispersio) hankinta | — | €3.0M | FI | 12/31/2025 | View on TED ↗ |
| 12/18/2024 | Pohjois-Pohjanmaan hyvinvointialue | Finland – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – Monoklonaaliset vasta-aineet ajalle 1.1.-31.12.2025 + optiovuosi 2026 | — | €28.0M | FI | — | View on TED ↗ |
| 05/17/2024 | Pirkanmaan hyvinvointialue | Finland – Medical equipments, pharmaceuticals and personal care products – Bulevirtidivalmisteen suorahankinta | — | €400.0K | FI | 12/31/2024 | View on TED ↗ |
| 04/12/2024 | Sansia Oy | Finland – Pharmaceutical products – Lääkevalmisteet sekä niihin rinnastettavat valmisteet Itä-Suomen yhteistyöalueelle | — | €130.0M | FI | — | View on TED ↗ |
| 02/29/2024 | HUS Group, the joint authority for Helsinki and Uusimaa | Finland – Antivirals for systemic use – Bulevirtidivalmiste (Hepcludex® 2 mg injektiokuiva-aine) suorahankinta | — | €1.2M | FI | 12/31/2024 | View on TED ↗ |
| 02/28/2024 | HUS Group, the joint authority for Helsinki and Uusimaa | Finland – Pharmaceutical products – Remdesiviirin (Veklury 100 mg kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos) suorahankinta | — | €1.0M | FI | 12/31/2024 | View on TED ↗ |
| 02/28/2024 | Pohjois-Savon hyvinvointialue | Finland – Other therapeutic products – Veklury 100 mg infuusiokuiva-aineen hankinta | — | €300.0K | FI | 03/31/2027 | View on TED ↗ |
| 02/19/2024 | Pirkanmaan hyvinvointialue | Finland – Medical equipments, pharmaceuticals and personal care products – Remdesiviiri-lääkevalmisteen suorahankinta | — | €370.0K | FI | 12/31/2024 | View on TED ↗ |
| 01/30/2024 | Pohjois-Pohjanmaan hyvinvointialue | Finland – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – Monoklonaaliset vasta-aineet ajalle 1.1-31.12.2024 + optiovuosi 2025 | — | €30.0M | FI | 12/31/2024 | View on TED ↗ |